REFERENCES
- Reichlin S. Somatostatin I and II. N Engl J Med 1983; 309: 1495-501, 1556–63.
- Van Hagen PM, Krenning EP, Kwekkeboom DJ, et al. Somatostatin and the immune and haematopoetic system; a review. Eur J Clin Invest 1994; 24: 91–9.
- Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997; 20: 348–67.
- Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobi-ology of somatostain. Crit Rev Neurobiol 1994; 8: 25–44.
- Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gas-trointestinal tract, and kidney. PNAS 1992; 89: 251–5.
- Yamada Y, Reisine T, Law SF, et al. Somatostatin receptors, an expanding gene family: cloning and functional characteri-zation of human SSTR3, a protein coupled to adenylyl cy-clase. Mol Endocrinol 1992; 6: 2136–42.
- Yamada Y, Kagimoto S, Kubota A, et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Communic 1993; 195: 844–52.
- Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn R. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663–6.
- Janson ET, Gobl A, Kälkner KM, öberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 1996; 56: 2561–5.
- Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somato-statin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr]octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716–31.
- Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, öberg K. [1111n-DTPA-D-Phel] Octreotide scintigraphy in patients with carcinoid tumors: the predictive value for so-matostatin analogue treatment. Eur J Endocrinol 1994; 131: 577–81.
- Krenning EP, Kooij PPM, Pauwels S, et al. Somatostatin receptor: Scintigraphy and radionuclide therapy. Digestion 1996; 57 (Suppl 1): 57–61.
- McLean JR, Blakey DH, Douglas GR, Bayley J. The Auger electron dosimetry of indium-111 in mammalian cells in vitro. Radiat Res 1989; 119: 205–18.
- Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-depen-dent regulation of cloned human somatostatin receptor types 1-5 (hSSTr1-5): Subtype selective internalization or upregu-lation. Endocrinology 1996; 137: 4046–9.
- Westlin JE, Janson ET, Ahlstrom H, Nilsson S, öhrvall U, öberg K. Scintigraphy using 111-Indium labelled somatostatin analogue for localization of neuroendocrine tumors. Antib Immunoconjug Radiopharm 1992; 5: 367–84.
- Caro LG, van Turbengen RP, Roll JA. High-resolution au-toradiography. 1. Methods. J Cell Biol 1962; 15: 173–88.